MuLBSTA Score for Viral Pneumonia Mortality
Predicts 90-day mortality in patients hospitalised with viral pneumonia (derived in 528 patients, Ruijin Hospital, Shanghai). MuLBSTA = Multilobular infiltrates, hypo-Lymphocytosis, Bacterial co-infection, Smoking history, hyper-Tension, Age.
Score interpretation
MuLBSTA 0–11: 90-day mortality 5.1 % in the derivation cohort (Guo 2019).
→ Standard inpatient care for viral pneumonia; reassess if the patient deteriorates.
MuLBSTA ≥ 12: 90-day mortality 33.9 % in the derivation cohort (Guo 2019).
→ Close monitoring and early senior / critical care review; look for and treat bacterial co-infection; escalate care as appropriate.
Interpretation bands for the MuLBSTA Score. Apply clinical judgement and local guidance.
References
- Guo L, et al. Clinical features predicting mortality risk in patients with viral pneumonia: the MuLBSTA score. Front Microbiol. 2019;10:2752.
Related
Curated clinical cross-links plus same-class fallbacks.
- Pneumonia Severity Index (PSI/PORT) · Pneumonia
- CRB-65 Score for Community Pneumonia · Pneumonia
- SMART-COP Score for Pneumonia Severity · Pneumonia
- CURB-65 Score for Community-Acquired Pneumonia · Pneumonia
- DRIP Score for Drug-Resistant Pneumonia · Pneumonia
- SCAP Score for Severe Community-Acquired Pneumonia · Pneumonia
- Baloxavir Marboxil · Influenza Antiviral — Cap-Dependent Endonuclease Inhibitor
- Letermovir · CMV Antiviral — Viral Terminase Inhibitor (Prophylaxis in HSCT)
- Lefamulin · Pleuromutilin Antibiotic (Community-Acquired Pneumonia)
- Influenza vaccine (inactivated) · Vaccine
- Influenza vaccine (live attenuated, intranasal) · Vaccine
- Ceftriaxone (Paediatric) · Third-Generation Cephalosporin — Meningitis / Sepsis / Community-Acquired Pneumonia
- Acute Asthma in Adults · BTS/SIGN British Guideline on Asthma 2019; NICE NG80
- Pulmonary Embolism Assessment · NICE NG158; ESC 2019 PE Guidelines
- Acute Exacerbation of COPD (AECOPD) · NICE NG115; GOLD 2024
- Spontaneous Pneumothorax (Adult) · BTS Pleural Disease 2023
- Atypical Pneumonia (Legionella / Mycoplasma / Chlamydophila) · BTS 2023; IDSA
- COPD Exacerbation Management · NICE NG115 / GOLD 2024
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.